Search

DR-NET National DR Workshop in Tanzania: Policy, training and technology

Diabetic retinopathy (DR) is a leading cause of moderate to severe visual impairment (VI) and blindness worldwide, posing a significant public health challenge. As the prevalence of diabetes continues to rise globally, particularly in low- and middle-income countries (LMICs), the...

Sickle cell eye disease: an overview of vitreoretinal complications and their surgical management

Sickle cell disease is the most common genetic disorder worldwide and is associated with lifelong anaemia, intermittent pain and multi-organ morbidity. Ocular involvement can be associated with significant visual impairment due to the complications of proliferative sickle retinopathy (PSR). Occasionally...

Blinking blepharitis has a lot to answer for…

Never ignore the small things’…someone once said. There is no doubt blepharitis is one of the most common eye conditions encountered daily, but with the typical pressures of a busy outpatient department, the management of more obvious, sight-threatening conditions necessarily...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Ophthalmology research: lessons from the Academic Foundation Programme

The author discusses practical lessons learned during eight months of ophthalmology research as a guide for candidates considering a research themed AFP post, with general tips for anyone undertaking research whilst balancing clinical duties. Ophthalmology is already one of the...

The impact of obstructive sleep apnoea monitoring functionality on smartwatches: a new frontier for ophthalmologists

Dawn of a new era in wearable technology? Smartwatches have really stepped up their game and have evolved from telling time to keeping an eye on our health. In February 2024, the United States Food and Drug Administration (FDA) gave...

General purpose AI: Transitioning from high performance in highly curated settings to useful applications in ophthalmology

Artificial intelligence (AI) may be understood as the ability of machines to perform tasks which otherwise require human perception, reasoning, or learning. With the advent of deep learning, AI has achieved remarkable results across a wide range of medical tasks...